Impact of Airway Inflammation on Mitochondria
气道炎症对线粒体的影响
基本信息
- 批准号:10225165
- 负责人:
- 金额:$ 68.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAffectAirway DiseaseAsthmaAwarenessBiogenesisCOVID-19 pandemicChemicalsConsumptionContractile ProteinsEndoplasmic ReticulumEnzymesExperimental DesignsFailureGenerationsGoalsHumanIndividualInflammationInflammatoryInositolLung diseasesMediatingMessenger RNAMitochondriaMolecular ChaperonesMuscle MitochondriaOxidative StressPINK1 genePathway interactionsPhosphorylationPlasmidsProteinsRNA SplicingReactive Oxygen SpeciesResearchSignal TransductionSiteSmall Interfering RNASmooth Muscle MyocytesStressStructureTNF geneTestingTransfectionUbiquitinationairway inflammationcytokinedensityendoplasmic reticulum stressknock-downloss of functionmeetingsmutantnoveloverexpressionpandemic diseaseparkin gene/proteinprotein expressionrespiratoryrespiratory smooth muscleresponse
项目摘要
The impact of acute airway inflammation is mediated by pro-inflammatory cytokines (e.g., TNFα),
and underlies a number of respiratory diseases. A fundamental question is why are some
individuals more susceptible than others to the negative impact of airway inflammation. We will
explore a novel homeostatic mechanism, which protects airway smooth muscle (hASM) cells from
the negative impact of inflammation-induced reactive oxygen species (ROS) formation and
protein unfolding (endoplasmic reticulum (ER) stress). We believe that a failure in this homeostatic
mechanism leads to increased ROS formation thereby exacerbating oxidative and ER stress.
Overall Hypothesis: TNFα-induced ROS formation and protein unfolding activates the
pIRE1α/XBP1s ER stress pathway in hASM, which initiates a homeostatic response directed
towards increasing mitochondrial biogenesis and mitochondrial volume density to reduce O2
consumption and ROS formation by individual mitochondrion, while still meeting the increase in
ATP demand – sharing the energetic load across mitochondria. Furthermore, reduced Mfn2
disrupts mitochondrial tethering to the ER, thereby decreasing mitochondrial Ca2+ influx and
maximum respiratory capacity of mitochondria.
Aim 1: TNFα-induced activation of pIRE1α/XBP1s ER stress pathway increases mitochondrial
volume density and reduces O2 consumption and ROS formation per mitochondrion.
In hASM cells, the downstream impact of TNFα-induced activation of the pIRE1α/XBP1s ER
stress pathway will be explored using transfection of a non-phosphorylatable IRE1α mutant
plasmid (DP-IRE1α) or an unspliceable XBP1 (uXBP1) mRNA. In addition, we will examine the
effects of siRNA knockdown of PGC1α and Mfn2 overexpression on TNFα-induced changes in
mitochondrial biogenesis, mitochondrial volume density, O2 consumption and ROS formation.
Aim 2: TNFα-induced reduction in Mfn2 disrupts mitochondrial tethering to ER, decreases
mitochondrial Ca2+ influx and reduces maximum respiratory capacity of mitochondria.
In hASM cells, we will examine the impact of DP-IRE1α or uXBP1 mRNA transfection and
siRNA Mfn2 knockdown on TNFα-induced disruption of mitochondrial/ ER tethering, decreased
mitochondrial Ca2+ influx and reduced maximum respiratory capacity of mitochondria.
Aim 3: The impact of TNFα on activation of the pIRE1α/XBP1s ER stress pathway and
downstream effects are mitigated by ROS scavenging and chemical chaperone treatment.
In hASM cells, the mitigating effects of ROS scavenging and chemical chaperone treatment
on TNFα-induced activation of the pIRE1α/XBP1s ER stress pathway will be examined.
急性气道注射的影响是由促炎性细胞因子(例如TNFα),
并构成了许多呼吸道疾病。一个基本的问题是为什么有些
比其他人更容易受到气道注射的负面影响。我们将
探索一种新型的稳态机制,该机制可保护气道平滑肌(HASM)细胞免受
炎症诱导的活性氧(ROS)形成的负面影响和
蛋白质展开(内质网(ER)应力)。我们相信这种体内平衡的失败
机制导致ROS的形成增加,从而加剧氧化和ER应激。
总体假设:TNFα诱导的ROS形成和蛋白质展开激活
HASM中的Pire1α/XBP1S ER应力途径,该途径启动了定向的稳态反应
旨在增加线粒体生物发生和线粒体体积密度以降低O2
单个线粒体的消费和ROS形成,同时仍达到增加
ATP需求 - 共享线粒体的能量负载。此外,MFN2降低
破坏线粒体绑扎到ER,从而降低线粒体Ca2+影响和
线粒体的最大呼吸能力。
AIM 1:TNFα诱导的PIRE1α/XBP1S ER应力途径的激活增加了线粒体
量密度并降低每线粒体的O2消耗和ROS形成。
在HASM细胞中,TNFα诱导的PIRE1α/XBP1S ER激活的下游影响
将使用非磷酸化IRE1α突变体的转化来探索应力途径
质粒(DP-ire1α)或不可裂解的XBP1(UXBP1)mRNA。此外,我们将研究
PGC1α和MFN2过表达的siRNA敲低对TNFα诱导的变化的影响
线粒体生物发生,线粒体体积密度,O2消耗和ROS形成。
AIM 2:TNFα诱导的MFN2降低会破坏线粒体束缚至ER,下降
线粒体Ca2+影响并降低线粒体的最大呼吸能力。
在HASM细胞中,我们将检查DP-IRE1α或UXBP1 mRNA转染和
TNFα诱导的线粒体/ ER链接的破坏,siRNA MFN2敲低降低
线粒体CA2+影响线粒体的最大呼吸能力。
AIM 3:TNFα对PIRE1α/XBP1S ER应力途径激活的影响
通过ROS清除和化学伴侣治疗可以减轻下游效应。
在HASM细胞中,ROS清除和化学链酮处理的缓解作用
将检查TNFα诱导的PIRE1α/XBP1S ER应力途径的激活。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Y. S. Prakash其他文献
Y. S. Prakash的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Y. S. Prakash', 18)}}的其他基金
Interdisciplinary Training in Lung Physiology and Biomedical Engineering
肺生理学和生物医学工程跨学科培训
- 批准号:
9883824 - 财政年份:2012
- 资助金额:
$ 68.37万 - 项目类别:
Interdisciplinary Training in Lung Physiology and Biomedical Engineering
肺生理学和生物医学工程跨学科培训
- 批准号:
9207236 - 财政年份:2012
- 资助金额:
$ 68.37万 - 项目类别:
相似国自然基金
COPD气道黏液高分泌的CFTR调控机制及全真一气汤对其影响研究
- 批准号:81774103
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:面上项目
受肺内微生物影响的NODAL分子在气道高反应性疾病中的作用及分子机制的研究
- 批准号:31670121
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
Notch信号通路影响气道平滑肌细胞合成基质金属蛋白酶12以促进COPD的机制探讨
- 批准号:81300031
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
NADPH氧化酶和线粒体UCP2蛋白影响人气道平滑肌细胞氧化/抗氧化平衡的作用及机制
- 批准号:81360004
- 批准年份:2013
- 资助金额:49.0 万元
- 项目类别:地区科学基金项目
慢性阻塞性肺疾病中DNA加合物对气道表遗传学和慢性炎症影响的研究
- 批准号:81070036
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 68.37万 - 项目类别:
Heterogeneity and cellular hierarchy of lung cDC2
肺 cDC2 的异质性和细胞层次
- 批准号:
10665348 - 财政年份:2023
- 资助金额:
$ 68.37万 - 项目类别:
Dose escalation clinical trial of high-dose oral montelukast to inform future RCT in children with acute asthma exacerbations
大剂量口服孟鲁司特的剂量递增临床试验为哮喘急性发作儿童的未来随机对照试验提供信息
- 批准号:
10649012 - 财政年份:2023
- 资助金额:
$ 68.37万 - 项目类别:
Neuroimmune interactions for laryngeal sensorimotor neuropathy in postviral influenza infection
病毒性流感感染后喉部感觉运动神经病变的神经免疫相互作用
- 批准号:
10827254 - 财政年份:2023
- 资助金额:
$ 68.37万 - 项目类别: